RXRX — Recursion Pharmaceuticals, Inc.
7 mentions in the last 24 hours · 0.04% of all mentions
Why people talked about RXRX (2026-11-03)
- Recursion Pharmaceuticals reported Q3 2026 earnings with revenue of $18.6M and EPS of -$0.22, both beating estimates.
- The company announced the appointment of Mr. Hassan as Chair of the Board via a press release.
- New Phase 2 data for REC-4881 was presented, showing deep and durable polyp burden reductions in FAP patients.
| Bluesky | 5 | community |
| GDELT | 1 | news |
| SEC EDGAR 8-K | 1 | filings |